## **Angel Artal**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7075022/publications.pdf

Version: 2024-02-01

623734 677142 6,522 21 14 22 citations g-index h-index papers 23 23 23 7339 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 239-246.	10.7	4,943
2	Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 1999, 17, 12-12.	1.6	438
3	Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients. Clinical Cancer Research, 2004, 10, 1318-1325.	7.0	345
4	Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer. Annals of Oncology, 2004, 15, 1194-1203.	1.2	270
5	Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non–Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial. Journal of Clinical Oncology, 2003, 21, 3207-3213.	1.6	177
6	Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology, 2007, 25, 4736-4742.	1.6	104
7	Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2001, 19, 1071-1077.	1.6	45
8	Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 1998, 22, 139-148.	2.0	37
9	Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Annals of Oncology, 2005, 16, 597-601.	1.2	23
10	Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anti-Cancer Drugs, 2001, 12, 713-717.	1.4	20
11	Bilateral Choroidal Metastases Revealing an Advanced Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2009, 88, 1013-1015.	1.3	19
12	Brain Metastases from Colorectal Carcinoma. Tumori, 2001, 87, 332-334.	1.1	17
13	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. Future Oncology, 2015, 11, 267-277.	2.4	17
14	Three-week schedule of irinotecan and cisplatin in advanced non-small cell lung cancer: a multicentre phase II study. Lung Cancer, 2003, 39, 201-207.	2.0	14
15	Preoperative High-Dose Cisplatin Versus Moderate- Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial. Clinical Lung Cancer, 2000, 1, 287-293.	2.6	12
16	Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. Lung Cancer, 2000, 30, 107-116.	2.0	12
17	Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?. Lung Cancer, 2010, 68, 415-419.	2.0	8
18	Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study. Future Oncology, 2015, 11, 1665-1674.	2.4	6

## ANGEL ARTAL

#	Article	IF	CITATION
19	Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. Journal of Thoracic Oncology, 2018, 13, e76-e77.	1.1	5
20	Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS). Clinical and Translational Oncology, 2011, 13, 328-334.	2.4	4
21	SEOM clinical guidelines for the treatment of small-cell lung cancer. Clinical and Translational Oncology, 2010, 12, 27-31.	2.4	2